

# Special Issue

## New Trends in Cancer Immunotherapy

### Message from the Guest Editor

Cancer is the second-leading cause of mortality globally. Cancer immunotherapy is a cutting-edge approach, which utilizes the immune system to identify and eradicate cancer cells. Nowadays, some of the most promising ways to treat cancer include therapeutic cancer vaccines, immune checkpoint inhibitors (like CTLA-4 and PD-1), bi-specific T-cell engagers (BiTEs), and adoptive cell therapies (ACTs). The stimulation of the T-cell-based immune response against tumor antigens by either endogenous or modified T cells is the common ground for all the scientific advances described above. Cancer immunotherapies are effective due to the interactions between the innate immune system, namely antigen-presenting and effector cells (T- and NK cells). Current methods that utilize these cells are under development.

Our goal in publishing this Special Issue "New Trends in Cancer Immunotherapy" is to further enhance the scientific interest in cancer immunotherapies, helping us to understand their mode of action, advantages, and limitations. This will promote the development of novel strategies for optimal clinical efficacy.

---

### Guest Editor

Dr. Markella Zannikou

Feinberg School of Medicine, Northwestern University, 303 East Superior Ave., Chicago, IL 60611, USA

---

### Deadline for manuscript submissions

31 May 2026



# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9

CiteScore 6.8

Indexed in PubMed



[mdpi.com/si/209433](https://www.mdpi.com/si/209433)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
biomedicines@mdpi.com

[mdpi.com/journal/  
biomedicines](https://www.mdpi.com/journal/biomedicines)





# Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](http://mdpi.com/journal/biomedicines)

## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

